

---

## AcouSort to participate in the prestigious NIH Research Festival

AcouSort has been selected to participate in the yearly NIH Research Festival arranged by the prestigious American National Institute of Health (NIH). The event takes place September 18-22 and gathers a wide range of NIH researchers. The research festival includes lectures, workshops, posters, and biotech vendor booths.

This year's festival is the first festival since the end of the COVID-19 pandemic. To participate as a vendor, you have to apply and be selected by the research festival committee. AcouSort has been chosen to participate in the vendor exhibition and has also been selected to host a 45-minute workshop demonstrating the Company's technology in more detail.

*"It is very exciting to be selected to this event where we will have the opportunity to show our AcouTrap technology to the NIH research community. The event usually gathers significant participation and being able to host a 45-minute workshop gives us a great opportunity to build closer relations with the researchers,"* says Kelley Intehar, AcouSort's General Manager and Sales Director North America.

### For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

---

### About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.